As of Oct 8, 2026 close
- Market cap
- $1.56B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $12.73$39.89
- Volume (live)
- -
- Avg. volume (3M)
- 6.02M
Ultragenyx Pharmaceutical (RARE) Stock Price & Financial Analysis
Ultragenyx Pharmaceutical Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $14.43 - $15.52 |
|---|---|
| 52-Week High | $39.89 |
| 52-Week Low | $12.73 |
| Open | $14.79 |
| Volume (last close) | 5.40M |
| Average Volume (3M) | 6.02M |
| Market Cap | 1.56B |
|---|---|
| Shares Outstanding | 101.90M |
| Price to Sales (P/S) | 2.17 |
| Price to Book (P/B) | -5.49 |
| EV/EBITDA | -5.57 |
| Revenue (TTM) | 716.93M |
|---|---|
| Net Income (TTM) | -586.41M |
| Free Cash Flow (TTM) | -489.00M |
| EPS (TTM) | $-5.83 |
| Profit Margin | -81.79% |
| Operating Margin | -73.77% |
| 50-Day MA | $20.28 |
|---|---|
| 200-Day MA | $23.71 |
| 1-Year Change | −51.71% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Ultragenyx Pharmaceutical at a Glance
Ultragenyx Pharmaceutical (RARE) has a market capitalization of $1.56B. The stock trades at 2.2× sales. Over the trailing twelve months it lost $586.41M on revenue of $716.93M and burned $489.00M of free cash flow. Revenue grew 17.5% year over year.
It holds $125.00M in cash and securities against $1.20B of debt, a net debt position of $1.08B.
Ultragenyx Pharmaceutical does not currently pay a dividend.
The share price is down 51.7% over the past year. At $15.29 it sits near the bottom of its 52-week range of $12.73 to $39.89, below its 200-day moving average of $23.71.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $26.88, 75.8% above the latest close.
Frequently Asked Questions About Ultragenyx Pharmaceutical
What is the current stock price for RARE?
As of the Oct 8, 2026 close, RARE stock trades at $15.29. The 52-week range is $12.73–$39.89, with a day range of $14.43–$15.52.
What is the P/E ratio for RARE?
The P/E ratio (Price-to-Earnings) for RARE is shown in the Key Statistics section. This valuation metric helps compare Ultragenyx Pharmaceutical Inc. to industry peers.
Does RARE pay dividends?
Ultragenyx Pharmaceutical does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for RARE?
Based on 8 analysts, the consensus for RARE is Buy.
What is the market cap of RARE?
Ultragenyx Pharmaceutical's market capitalization is $1.56B, classifying it as a small-cap company. Ultragenyx Pharmaceutical operates in the Healthcare sector within the Biotechnology industry.